PDCD1 and melanoma: The classifier was then applied to an independent melanoma anti-PD1 validation cohort from Riaz et al.8 (n = 51), and the predicted clusters significantly stratified patient overall survival (log-rank test, p = 0.0026) (Fig. 3A).